Luspatercept was approved for medical use in the European Union in June 2020.The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015. Research
Luspatercept is being evaluated for use in adults with non-transfusion dependent beta thalassemia. References
External links
"Luspatercept". Drug Information Portal. U.S. National Library of Medicine.
Necrolytic acral erythema is a cutaneous condition that is a manifestation of hepatitis C viral infection or zinc deficiency.It is a papulosquamous and sometimes vesiculobullous eruption bearing clinical and histologic similarity to other necrolytic erythemas such as necrolytic migratory erythema, pseudoglucagonoma and nutritional deficiency syndromes. See also
List of cutaneous conditions

References


== External links ==